Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide

Table 3

Fasting and postprandial profiles of the measured parameters in patients receiving exenatide and liraglutide on visit 1.

Parameters	0	120	240	𝑃	𝑃^∗
Triglycerides (mmol/L)
Exenatide	3.03±4.69	3.18±4.24	3.48±4.23	0.185	0.147
Liraglutide	2.42±2.97	2.47±2.47	2.53±2.59	0.628
Total cholesterol (mmol/L)
Exenatide	5.05±1.42	5.06±1.41	5.20±1.50	0.048	0.232
Liraglutide	5.15±1.19	5.00±1.00	5.24±1.16	0.016
HDL (mmol/L)
Exenatide	1.03±0.33	1.04±0.30	1.03±0.33	0.622	0.392
Liraglutide	1.19±0.45	1.17±0.44	1.19±0.45	0.597
LDL (mmol/L)
Exenatide	3.00±1.26	3.00±1.23	3.04±1.29	0.041	0.461
Liraglutide	2.87±0.71	2.80±0.63	2.85±0.63	0.187
Glucose (mmol/L)
Exenatide	7.33±2.73	6.50±1.44	5.91±1.84	0.032	0.803
Liraglutide	6.69±0.93	6.06±1.20	5.08±0.53	<0.0001
Insulin (pmol/L)
Exenatide	159.86±84.58	232.67±131.82	153.00±117.10	0.006	0.424
Liraglutide	152.07±49.74	208.39±111.16	105.07±63.80	0.002

Data are means ± SD. 𝑃 indicates the result of ANOVA for repeated measurements within each group (𝑃 value for the effect of time); 𝑃^∗ indicates the result of ANOVA for repeated measurements between the two groups (exenatide versus liraglutide) (time × group interaction).